ABSTRACT
Biomarkers, as compared to a true (primary) endpoint such as survival, can
often be measured earlier, easier, and more frequently and are less subject to
competing risks, and less confounded. The utilization of biomarkers will lead
to a better target population with a larger effect size, a smaller sample-size
required, and faster decision-making. With the advancement of proteomic,
genomic and genetic technologies, personalized medicine with the right drug
for the right patient becomes possible.
